185 related articles for article (PubMed ID: 30523754)
1. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
Burstein HJ; Lacchetti C; Griggs JJ
J Oncol Pract; 2019 Feb; 15(2):106-107. PubMed ID: 30523754
[No Abstract] [Full Text] [Related]
2. Prolactin and endocrine therapy resistance in breast cancer: The next potential hope for breast cancer treatment.
Li Y; Kong X; Xuan L; Wang Z; Huang YH
J Cell Mol Med; 2021 Nov; 25(22):10327-10348. PubMed ID: 34651424
[TBL] [Abstract][Full Text] [Related]
3. Balancing the risks and benefits of extended adjuvant endocrine therapy.
Jhaveri KL
Clin Adv Hematol Oncol; 2019 Feb; 17(2):105-108. PubMed ID: 30845113
[No Abstract] [Full Text] [Related]
4. Case Report: Long-Term Response to Pembrolizumab Combined With Endocrine Therapy in Metastatic Breast Cancer Patients With Hormone Receptor Expression.
Wu D; Tang S; Ye R; Li D; Gu D; Chen R; Zhang H; Sun J; Chen Z
Front Immunol; 2021; 12():610149. PubMed ID: 33692787
[TBL] [Abstract][Full Text] [Related]
5. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.
Chia YH; Ellis MJ; Ma CX
Br J Cancer; 2010 Sep; 103(6):759-64. PubMed ID: 20700118
[TBL] [Abstract][Full Text] [Related]
7. [Pharmaceutical therapy of breast cancer].
Láng I; Kahán Z; Pintér T; Dank M; Boér K; Pajkos G; Faluhelyi Z; Pikó B; Eckhardt S; Horváth Z
Magy Onkol; 2010 Sep; 54(3):237-54. PubMed ID: 20870601
[No Abstract] [Full Text] [Related]
8. Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer.
Bilgin B; Şendur MA; Hızal M; Akıncı MB; Dede DŞ; Yalçın B
Future Oncol; 2019 Jan; 15(2):105-107. PubMed ID: 30484708
[No Abstract] [Full Text] [Related]
9. Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy.
Yoon TI; Hwang UK; Kim ET; Lee S; Sohn G; Ko BS; Lee JW; Son BH; Kim S; Ahn SH; Kim HJ
Breast Cancer Res Treat; 2017 Sep; 165(2):311-320. PubMed ID: 28601930
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary.
Burstein HJ; Lacchetti C; Griggs JJ
J Oncol Pract; 2016 Apr; 12(4):390-3. PubMed ID: 26931400
[No Abstract] [Full Text] [Related]
11. Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.
Ohno S
Clin Breast Cancer; 2016 Aug; 16(4):238-46. PubMed ID: 27151773
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer update.
Kuter I
Oncologist; 2000; 5(4):285-92. PubMed ID: 10964995
[TBL] [Abstract][Full Text] [Related]
13. Extended adjuvant chemotherapy in endocrine non-responsive disease.
Colleoni M; Munzone E
Breast; 2013 Aug; 22 Suppl 2():S161-4. PubMed ID: 24074780
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.
Giordano SH; Freedman RA; Somerfield MR;
J Clin Oncol; 2022 Jan; 40(3):307-309. PubMed ID: 34878801
[No Abstract] [Full Text] [Related]
15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
16. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.
Ribnikar D; Bedard PL
Future Oncol; 2017 Dec; 13(30):2733-2736. PubMed ID: 29168649
[No Abstract] [Full Text] [Related]
17. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
19. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer.
Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]